Accelovance

What Accelovance does

Accelovance is presented in firmographic data as a private, US-headquartered contract research organization (CRO) founded in 2004 and based in Rockville, Maryland, with 501–1,000 employees. However, the bulk of the available operating evidence describes a global CRO identity closely matching Linical — publicly listed on the Tokyo Stock Exchange (2183:JP), founded in 2005, and headquartered in Osaka, Japan — suggesting Accelovance may have been consolidated into or rebranded under the Linical platform. The combined entity operates a full-service CRO model organized around two service pillars: Drug Development Strategy (protocol design, regulatory affairs, regulatory consulting, quality assurance, medical writing) and Clinical Trial Management (feasibility, project management, medical affairs/pharmacovigilance, clinical monitoring, patient recruitment, biometrics, training academy), with a Functional Services Provider (FSP) offering listed as in development.

Therapeutic expertise spans oncology, neurology and psychiatry, immunology and vaccines, endocrinology and metabolic disorders, and specialty areas including biosimilars, rare disease, and pediatrics, with services delivered across early-phase through late-phase studies. Operations span 30+ countries across the Americas, Europe, and Asia Pacific, with documented PMDA-led regulatory expertise in Japan and FDA submission experience in the US. The company reports 600+ studies conducted in the past five years, 85%+ client retention, and 80%+ of studies beating enrollment goals. Recognitions include Best Global CRO 2024, Best Vaccine CRO (World Vaccine Congress), 2025 GHP Award Winner, and ISO-IEC-27001 certification.

The business model is professional services-based with multi-year enterprise contracts; engagements are initiated through a direct "Request a Proposal" sales motion targeting mid-sized biotechnology and biopharmaceutical sponsors. Pricing is quote-based with no public tiers disclosed, and go-to-market is enterprise field sales rather than self-service. Distribution relies on direct B2B engagement supported by an investigator network for site relationships and a content-driven marketing approach via a Resource Center of articles, case studies, and white papers.

Name

Accelovance

Legal name

Linical

Website

https://accelovance.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Accelovance is a US-based contract research organization providing full-service clinical development to mid-sized biotech and biopharmaceutical sponsors, with operations spanning 30+ countries across oncology, CNS, vaccines, and metabolic therapeutic areas.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Professional, Scientific, and Technical Services (54)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Contract research services
• Clinical trial management
• Oncology clinical research
• Vaccine clinical trials
• Drug development strategy

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing comprehensive clinical development services including drug development strategy, clinical trial management, and functional services to pharmaceutical and biotechnology companies
2. Functional Services Provider (FSP): Offering functional service provider model as part of CRO services portfolio

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Accelovance is a global Contract Research Organization that delivers full-service clinical development services to pharmaceutical and biotechnology sponsors, with therapeutic specialization in oncology, vaccines, and general medicine. The portfolio spans drug development strategy (protocol design, regulatory affairs, quality assurance, medical writing) and clinical trial management (feasibility, project management, clinical monitoring, patient recruitment, biometrics, pharmacovigilance), complemented by a Functional Services Provider (FSP) model and global operations across 30+ countries.

Product overview

Linical is an award-winning, global Contract Research Organization (CRO) providing comprehensive clinical development services. The portfolio consists of two core service pillars: Drug Development Strategy (including protocol development, regulatory affairs, regulatory consulting, quality assurance, and medical writing) and Clinical Trial Management (covering feasibility, project management, medical affairs, pharmacovigilance, clinical monitoring, patient recruitment, biometrics, and training). The company also offers a Functional Services Provider (FSP) model. Therapeutic expertise spans oncology, neurology & psychiatry, immunology & vaccines, endocrinology & metabolic, and other focus areas such as biosimilars, rare disease, and pediatrics. Services are delivered across clinical trial phases from early-phase through late-phase studies, with global operations covering The Americas, Europe, and Asia Pacific across more than 30 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Linical: Global CRO providing drug development strategy and clinical trial management services across Americas, Europe, and Asia Pacific.

Products and services

• Clinical Research Services Full-service CRO offering comprehensive clinical development services — including drug development strategy, clinical trial management, and functional services — delivered to pharmaceutical and biotechnology sponsors across the Americas, Europe, and Asia Pacific.
• Clinical Trial Management Full-range clinical trial management services providing flexibility and experience to bring products to market, covering feasibility, project management, clinical monitoring, patient recruitment, biometrics, and pharmacovigilance.
• Drug Development Strategy Customized clinical trial planning service that proactively tackles obstacles, optimizes trial design, and positions trials for success through regulatory strategy, quality assurance, and medical writing.
• Functional Services Provider (FSP) Flexible functional service provider model providing managed resourcing and functional support across the clinical development lifecycle for sponsors seeking embedded or hybrid resourcing models.
• Oncology Therapeutic Services Specialized oncology clinical trial services covering solid tumors, liquid tumors, immunotherapies, rare cancers, and early-phase oncology studies for pharmaceutical and biotechnology sponsors.
• Vaccine & Immunology Therapeutic Services Award-winning immunology and vaccine trial services covering prophylactic and therapeutic vaccines, outbreak and epidemic response, allergic and autoimmune disorders, and respiratory disorders.

Quantifiable outcome

• 85%+ client retention rate demonstrating high satisfaction and repeat business
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• IQVIA: IQVIA is the world's largest CRO, offering full-service clinical development, technology-enabled trial solutions, and real-world data across all therapeutic areas. Directly competes with Linical/Accelovance for global clinical trial management engagements, particularly in oncology and Phase II/III work.
• ICON plc: ICON is a top-tier global CRO with broad therapeutic-area coverage and a leading FSP business. Directly competes with Linical/Accelovance for full-service and functional outsourcing engagements with pharma and biotech sponsors.
• Labcorp Drug Development (formerly Covance): Labcorp's Drug Development division is a major global CRO providing full-service clinical development and central laboratory services. Directly competes in clinical trial management across multiple therapeutic areas, including oncology and vaccines.
• Charles River Laboratories: Charles River provides early-stage CRO services, discovery, and safety assessment, increasingly expanding into full-service clinical development. Directly competes for early-phase oncology and vaccine trial work, and overlaps with Linical/Accelovance on Phase I/II oncology programs.
• PPD (Thermo Fisher Scientific): PPD is a global CRO providing full-service clinical development, lab services, and site management, now part of Thermo Fisher. Directly competes for full-service clinical trial engagements with pharma and biotech sponsors across therapeutic areas including oncology.
• Parexel: Parexel is a global mid-to-large CRO with strong biopharma sponsor relationships and expertise in oncology and CNS. Directly competes with Linical/Accelovance for full-service and FSP engagements, particularly from mid-sized biotech sponsors.
• Medpace: Medpace is a mid-sized, full-service CRO with a strong oncology and specialty therapeutic focus and an organic-growth, scientist-led model. Directly competes for mid-sized biotech clinical trial engagements, especially in oncology, mirroring Linical/Accelovance's positioning.
• Syneos Health: Syneos Health is a global biopharma solutions organization offering clinical development and commercialization services. Directly competes for full-service clinical trial engagements, though its broader commercialization scope differentiates it slightly.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO specializing in neuroscience, oncology, cardiometabolic, and rare diseases. Closely comparable in scale and therapeutic-area focus, competing for the same mid-sized biotech sponsors.

Emerging players

• WuXi AppTec: WuXi AppTec is a leading Asia-based CRO/CDMO with rapidly expanding global clinical development capability. Competes in oncology trial services and Asia-Pacific trial execution, and represents an emerging global alternative for sponsors seeking non-Western CRO partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/accelovance
• Facebookfacebook.com/accelovance
• LinkedInlinkedin.com/company/accelovance

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accelovance